Despite the introduction of seven newly FDA-approved gram-negative antibiotics, specifically designed to combat infections induced by pathogens exhibiting difficult-to-treat resistance, many practitioners and clinicians continue to subscribe to the less efficacious and potentially riskier, generically traditional counterpart antibiotics. This finding was highlighted in a study published in the Annals of Internal Medicine.  A retrospective cohort…